Introduction
The main-chain atoms of Lys-103 are exposed to the NNRTI pocket of the HEPT analogues and represent a site of potential hydrogen bonding. Indeed, the crystal structures of RT complexed with MKC-442 reveal the presence of a water molecule hydrogen bonding to the main-chain carbonyl oxygen of Lys-103, 3 Å away from the terminal methyl carbon atom of the N1-ethoxymethyl substituent of the inhibitor (Fig. 2) . This observation suggests that a suitable modification of N1-substituent could hydrogen bond directly.
A number of RT-NNRTI crystal structures provide information on the potential for the accommodation of various N1-substituents in the NNRTI binding pocket. The structure of RT complexed with TNK-651 (Hopkins et al., 1996) demonstrates that large N1-substituents can also bind in the binding pocket. Bulky N1-substituents are accommodated by the movement of Pro-236 and the flexibility of the backbone torsion angles in the region of residue 233 which allows the repositioning of the remaining β10 strand (residues 232-234), the Pro-236 loop and much of β11 (residues 239-241).
The recent determination of the crystal structure of RT complexed with bis(hetero-aryl)piperazine (BHAP) U-90152 (Esnouf et al., 1997) provides further evidence of the flexibility of the Pro-236 loop region. In the RT-BHAP structure, the indole group of the inhibitor makes considerable interactions with the pyrrolidine ring of Pro-236. The presence of the large indole ring forces the Pro-236 loop to adopt an even more open conformation than that observed in the RT-TNK-651 complex. BHAP hydrogen bonds to the main chain of Lys-103 via its carbonyl oxygen and indole nitrogen, clearly demonstrating that for an appropriate N1substituent such bonding is achievable.
The rationale of the present study was that the susceptibility of MKC-442 analogues to drug-resistant mutations might be reduced by improving the binding of the inhibitors by exploiting the possibility of additional hydrogen bonding to main-chain atoms or structural waters. Theoretical studies (Wang & Ben-Naim, 1996) propose that the addition of hydrophilic groups to an inhibitor which form bridging hydrogen bonds to the protein, via a water molecule, could provide additional binding energy.
Exploitation of the potential for hydrogen bonding mainchain atoms of Lys-103, or the associated water molecule, can be investigated by the incorporation of hydrophilic functional groups such as an ester or a primary amide group after an alkyl chain of n carbon atoms from the N1-position. Superposition modelling indicates that an alkyl link of n=1 carbon atom, as shown in compounds 8 and 13, is too short for these groups to hydrogen bond to either the Lys-103 main-chain atoms or the water molecule hydrogen bonding to the carbonyl oxygen of Lys-103. The ester carbonyl oxygen of compound 8 is, however, capable of hydrogen bonding to the nearby hydroxyl group of Tyr-318. This is also the case for compound 13, either of the polar atoms of the amide group being capable of forming a hydrogen bond to the Tyr-318 hydroxyl group, however the hydrophilic amide is in an energetically unfavourable environment surrounded by the hydrophobic residues, Val-106, Pro-225, Phe-227 and Pro-236. Alternatively, given the additional degrees of freedom of the n=1 alkyl chain, these hydrophilic groups can adopt conformations which would enable a water molecule to form a bridging hydrogen bond to the HIV-1 RT is modelled according to the data of Hopkins et al., 1996) . The figure was produced as a ball-and-stick representation using the program Molscript (Kraulis, 1991) . The protein is shown with sticks joining the atoms. Bound water molecules are drawn slightly larger. Hydrogen bond linkings are shown by dotted lines. Note the large number of hydrophobic and aromatic protein side-chains in close proximity to the inhibitor. Medium-length alkyl chains allow the water molecule (hydrogen bonding to the carbonyl oxygen of Lys-103) in the RT-MKC-442 structure to be targeted. Modelling suggests that interaction with the water molecule could be directly exploited by replacing the N1-ethoxymethyl group of MKC-442 with a hydrophilic group with an optimum alkyl chain length of n=3. Compounds 9, 12 and 14 fall in this category.
Longer alkyl chains (n>3) would require the movement of Pro-236 to accommodate the substituent and appear to be less favourable. In particular, the ester carbonyl oxygen of compound 10 (n=4) or 11 (n=5) does not appear to be able to form hydrogen bonds to either the Lys-103 main chain or the associated water. However, with the additional hydrogen bonding potential of an amide group, compounds 15 (n=4) and 16 (n=5) have the possibility of forming hydrogen bonds directly with the main-chain atoms of Lys-103 or Val-106, or indirectly via a bridging water molecule depending on the conformation adopted.
Materials and Methods: Structural Modelling
Protein-inhibitor interactions were examined by simple structural modelling. Analogues of MKC-442 having an ω-functionalized N1-alkyl substituent were created by modifying the RT-bound MKC-442 model using the program SYBYL (Tripos Associates) on an R10000 Silicon Graphics Impact workstation and modelled into the MKC-442 binding site using the program FRODO ( Jones, 1985) on an Evans and Sutherland ESV graphics workstation.
Materials and Methods: Chemistry
Melting points were determined with a Yanagimoto micro melting point apparatus and are uncorrected. 1 H NMR spectra were measured at 23°C (internal standard, Me 4 Si) with either a JEOL JNM-GX 400 or a JEOL JNM-LA 500 spectrometer. Mass spectra (MS) were taken on a JEOL SX-102A spectrometer in FAB mode (m-nitrobenzyl alcohol as a matrix). Ultraviolet spectra (UV) were recorded on a JASCO Ubest-55 spectrophotometer. Column chromatography was performed on either silica gel (Silica Gel 60, Merck) or alumina (Aluminum oxide 90, Merck). Thin layer chromatography (TLC) was carried out on silica gel (precoated silica gel plate F 254 , Merck).
Preparation of 3 as a typical example for N1alkylation of 2 A mixture of 2 (1.03 mg, 2.84 mmol), finely powdered K 2 CO 3 (1.08 g), and methyl bromoacetate (620 mg, 4.05 mmol) in DMF (10 ml) was stirred for 1 h at 100°C. After evaporation of the solvent, the reaction mixture was purified by silica gel column chromatography (hexane:EtOAc; 5:1-2:1) to give a byproduct (82 mg, 7%) and 3 (1.05 g, 85%). Physical data of the byproduct obtained as a syrup are as follows: UV (MeOH) λ max 243 and 277 nm, λ min 220 and 263 nm; 1 H NMR (CDCl 3 ) δ 1.26 (6H, d, CHMe 2 ), 3.14 (1H, sept, CHMe 2 ), 3.62 (3H, s, CO 2 Me), 3.88 and 4.77 (4H, each as s, CH 2 Ph and OCH 2 ), 5.47 (2H, s, CH 2 COPh), 7.19-7.63 (8H, m, Ph), 7.99-8.01 (2H, m, Ph); FAB-MS m/z 435 (M + +H). Physical data of 3 are as follows: mp 126-129°C (MeOH); UV (MeOH) λ max 243 nm (ε 18500), λ shoulder 269 nm (ε 10100), λ min 224 nm (ε 10600); 1 H NMR (CDCl 3 ) δ 1.31 (6H, d, CHMe 2 ), 2.97 (1H, sept, CHMe 2 ), 3.66 (3H, s, CO 2 Me), 3.96 and 4.46 (4H, each as s, NCH 2 CO 2 Me and CH 2 Ph), 5.42 (2H, s, CH 2 COPh), 7.15-7.61 (8H, m, Ph), 7.99-8.01 (2H, m, Ph); FAB-MS m/z 435 (M + +H). Anal. calcd for C 25 H 26 N 2 O 5 : C, 69.11; H, 6.03; N, 6.45. Found: C, 69.40; H, 6.10; N, 6.42.
6-Benzyl-1-[3-(ethoxycarbonyl)]propyl-5-isopropyl-3-phenacyluracil (4)
This compound was obtained as a syrup by the procedure described for the preparation of 3. 1 H NMR (CDCl 3 ) δ 1.22 (3H, t, CO 2 CH 2 CH 3 ), 1.29 (6H, d, CHMe 2 ), 1.91-1.97 (2H, m, NCH 2 CH 2 CH 2 CO 2 Et), 2.30 (2H, t, CH 2 CO 2 Et), 2.93 (1H, sept, CHMe 2 ), 3.71 (2H, t, NCH 2 ), 4.11 (2H, q, CO 2 CH 2 CH 3 ), 4.16 (2H, s, CH 2 Ph), 5.42 (2H, s, CH 2 COPh), 7.18-8.02 (10H, m, Ph); FAB-MS m/z 477 (M + +H).
6-Benzyl-1-[4-(ethoxycarbonyl)]butyl-5-isopropyl-3-phenacyluracil (5)
This compound was obtained as a syrup by the procedure described for the preparation of 3. 1 H NMR (CDCl 3 ) δ 1.24 (3H, t, CO 2 CH 2 CH 3 ), 1.28 (6H, d, CHMe 2 ), 1.52-1.65 (4H, m, NCH 2 CH 2 CH 2 CH 2 ), 2.25 (2H, t, CH 2 CO 2 Et), 2.92 (1H, sept, CHMe 2 ), 3.70 (2H, t, NCH 2 ), 4.06 (2H, s, CH 2 Ph), 4.11 (2H, q, CO 2 CH 2 CH 3 ), (6) Reaction of the less polar byproduct, obtained in the preparation of 6, with Zn/AcOH: formation of 6-benzyl-5-isopropyluracil A suspension of the less polar byproduct (643 mg) and zinc powder (1.25 g) in AcOH (5 ml) was vigorously stirred at refluxing temperature for 3 h. After filtration, the reaction mixture was evaporated to dryness. Silica gel column chromatography (hexane:EtOAc; 2:1-1:1) of the resulting residue gave 6-benzyl-5-isopropyluracil (171 mg, 55%) as a solid, which was crystallized from CH 2 Cl 2 -MeOH (mp 246-247°C): 1 H NMR (DMSO-d 6 ) δ 1.06 (6H, d, CHMe 2 ), 2.50 (1H, sept, CHMe 2 ), 3.76 (2H, s, CH 2 Ph), 7.21-7.34 (5H, m, Ph), 10.70 and 10.87 (2H, each as br, NH); FAB-MS m/z 245 (M + +H). Anal. calcd for C 14 H 16 N 2 O 2 : C, 68.83; H, 6.60; N, 11.47. Found: C, 69.06; H, 6.68; N, 11.47.
6-Benzyl
-1-[ 5-(ethoxycarbonyl)]pentyl-5-iso- propyl-3-phenacyluracil
This compound was obtained as a syrup by the procedure described for the preparation of 3. 1 H NMR (CDCl 3 ) δ 1.28 (6H, d, CHMe 2 ), 1.77-1.80 (2H, m, NCH 2 CH 2 CH 2 OH), 2.86 (1H, sept, CHMe 2 ), 3.58 (2H, br, CH 2 OH), 3.92 (2H, t, NCH 2 ), 4.10 (2H, s, CH 2 Ph), 5.45 (2H, s, CH 2 COPh), 7.15-8.03 (10H, m, Ph); FAB-MS m/z 421 (M + +H).
Preparation of 8 from 3 as a typical example for removal of the N3-phenacyl group A suspension of 3 (740 mg) and zinc powder (2.0 g) in AcOH (10 ml) was vigorously stirred at refluxing temperature for 2 h. After filtration, the reaction mixture was evaporated to dryness. The resulting residue was chromatographed on a silica gel column (hexane:EtOAc; 2:1-1:1) to give 8 (483 mg, 90%), which was crystallized from MeOH ( 
This compound was obtained in 79% yield from 4 by the procedure described for the preparation of 8: mp 134-135°C (EtOH); UV (MeOH) λ max 273 nm (ε 7400), λ min 242 nm (ε 3400); 1 H NMR (CDCl 3 ) δ 1.23 (3H, t, CO 2 CH 2 CH 3 ), 1.29 (6H, d, CHMe 2 ), 1.89-1.95 (2H, m, NCH 2 CH 2 CH 2 ), 2.31 (2H, t, CH 2 CO 2 Et), 2.87 (1H, sept, CHMe 2 ), 3.66 (2H, t, NCH 2 ), 4.12 (2H, q, CO 2 CH 2 CH 3 ) 
6-Benzyl-1-[4-(ethoxycarbonyl)]butyl-5-isopropyluracil (10)
This compound was obtained as a syrup in 73% yield from 5 by the procedure described for the preparation of 8: UV (MeOH) λ max 274 nm (ε 10100), λ min 240 nm (ε 2100); 1 H NMR (CDCl 3 ) δ 1.25 (3H, t, CO 2 CH 2 CH 3 ), 1.28 (6H, d, CHMe 2 ), 1.53-1.64 (4H, m, NCH 2 CH 2 CH 2 CH 2 ), 2.26 (2H, t, CH 2 CO 2 Et), 2.86 (1H, sept, CHMe 2 ), 3.65 (2H, t, NCH 2 ), 4.01 (2H, s, CH 2 Ph), 4.12 (2H, q, CO 2 CH 2 CH 3 ), 7.13 (2H, d, Ph), 7.29 (1H, t, Ph), 7.37 (2H, t, Ph), 8.67 (1H, br, NH); FAB-MS m/z 373 (M + +H). Anal. calcd for C 21 H 28 N 2 O 4 : C, 67.72; H, 7.58; N, 7.52. Found: C, 67.78; H, 7.84; N, 7.54. 6-Benzyl-1-[5-(ethoxycarbonyl)]pentyl-5-isopropyluracil (11) 1.23-1.29 (this region contains 2H, NCH 2 CH 2 CH 2 CH 2 CH 2 CO 2 Et, which overlapped with CO 2 CH 2 CH 3 and CHMe 2 ), 1.52-1.60 (4H, m, NCH 2 CH 2 CH 2 CH 2 CH 2 ), 2.25 (2H, t, CH 2 CO 2 Et), 2.86 (1H, sept, CHMe 2 ), 3.63 (2H, t, NCH 2 ), 3.99 (2H, s, CH 2 Ph), 4.12 (2H, q, CO 2 CH 2 CH 3 ), 7.12 (2H, d, Ph), 7.29 (1H, t, Ph), 7.36 (2H, t, Ph), 8.47 (1H, br, NH); FAB-MS m/z 387 (M + +H). Anal. calcd for C 22 H 30 N 2 O 4 : C, 68.37; H, 7.82; N, 7.25. Found: C, 68.43; H, 8.00; N, 7.23.
6-Benzyl-1-[3-(hydroxy)propyl]-5-isopropyluracil (12)
A mixture of 7 (511 mg, 1.22 mmol) and Ac 2 O (0.3 ml, 3.17 mmol) in pyridine (3 ml) was stirred at room temperature overnight. The reaction mixture was evaporated to dryness and the residue was treated by the procedure described for the preparation of 8. The resulting dephenacylated product, which was isolated by silica gel column chromatography (hexane:EtOAc; 2:1-1:1), was treated with NH 3 /MeOH (10 ml). Silica gel column chromatography (5% EtOH in CHCl 3 ) of the deacetylation mixture gave 12 (49 mg, 41%): mp 162-163°C (MeOHether); UV (MeOH) λ max 274 nm (ε 8000), λ min 239 nm (ε 1100); 1 H NMR (CDCl 3 , after addition of D 2 O) δ 1.28 (6H, d, CHMe 2 ), 1.75-1.81 (2H, m, NCH 2 CH 2 ), 2.86 (1H, sept, CHMe 2 ), 3.57 (2H, t, CH 2 OH), 3.86 (2H, t, NCH 2 ), 4.06 (2H, s, CH 2 Ph), 7.12 (2H, d, Ph), 7.29 (1H, t, Ph), 7.36 (2H, t, Ph); FAB-MS m/z 303 (M + +H). Anal. calcd for C 17 H 22 N 2 O 3 : C, 67.53; H, 7.33; N, 9.26. Found: C, 67.35; H, 7.40; N, 9.16. 
6-Benzyl-1-(carbamoyl)methyl-5-isopropyluracil (13)
A mixture of 8 (230 mg) and 25% aqueous NH 4 OH (25 ml) was stirred at room temperature overnight. Evaporation of the reaction mixture followed by silica gel column chromatography (5% EtOH in CHCl 3 ) gave 13 (195 mg, 89%): mp 257-258°C (EtOH); UV (MeOH) λ max 269 nm (ε 11800), λ min 237 nm (e 2400); 1 H NMR (DMSO-d 6 ) δ 1.17 (6H, d, CHMe 2 ), 2.81 (1H, sept, CHMe 2 ), 3.89 (2H, s, NCH 2 ), 4.15 (2H, s, CH 2 Ph), 7.16 (2H, d, Ph), 7.18 (1H, br, CONH), 7.26 (1H, t, Ph), 7.35 (2H, t, Ph), 7.52 (1H, br, CONH), 11.26 (1H, br, NH); FAB-MS m/z 302 (M + +H). Anal. calcd for C 16 H 19 N 3 O 3 : C, 63.77; H, 6.36; N, 13.94. Found: C, 63.52; H, 6.50; N, 13 .87.
6-Benzyl-1-[3-(carbamoyl)propyl]-5-isopropyluracil (14)
A mixture of 9 (408 mg) and 25% aqueous NH 4 OH was stirred at room temperature for 3 days. Evaporation of the reaction mixture followed by alumina column chromatography (5% MeOH in CHCl 3 ) gave 14 (245 mg, 65%): mp 217-218°C (MeOH-H 2 O); UV (MeOH) λ max 273 nm (ε 6300), λ min 243 nm (ε 2800); 1 H NMR (DMSO-d 6 ) δ 1.16 (6H, d, CHMe 2 ), 1.67-1.73 (2H, m, NCH 2 CH 2 CH 2 ), 2.04 (2H, t, CH 2 CONH 2 ), 2.81 (1H, sept, CHMe 2 ), 3.53 (2H, t, NCH 2 ), 4.12 (2H, s, CH 2 Ph), 6.80 (1H, br, CONH), 7.18 (2H, d, Ph), 7.24 (1H, t, Ph), 7.26 (1H, br, CONH), 7.34 (2H, t, Ph), 11.20 (1H, br, NH) ; FAB-MS m/z 330 (M + +H). Anal. calcd for C 18 H 23 N 3 O 3 ·1/10H 2 O: C, 65.28; H, 7.06; N, 12.69. Found: C, 65.16; H, 7.14; N, 12.51. 
6-Benzyl-1-[4-(carbamoyl)butyl]-5-isopropyluracil (15)
A mixture of 10 (692 mg), 25% aqueous NH 4 OH (40 ml), and pyridine (10 ml) was heated at 100°C in a sealed tube overnight. The reaction mixture was evaporated and chromatographed on an alumina column (5% MeOH in CHCl 3 ) to give 15 (245 mg, 38%), which was crystallized from MeOH-H 2 O but showed no clear mp (sintering from 103°C): UV (MeOH) λ max 274 nm (ε 7800), λ min 240 nm (ε 1000); 1 H NMR (DMSO-d 6 ) δ 1.16 (6H, d, CHMe 2 ), 1.34-1.44 (4H, m, NCH 2 CH 2 CH 2 CH 2 ), 1.95 (2H, t, CH 2 CONH 2 ), 2.81 (1H, sept, CHMe 2 ), 3.55 (2H, t, NCH 2 ), 4.04 (2H, s, CH 2 Ph), 6.66 (1H, br, CONH), 7.18 (2H, d, Ph plus 1H, CONH), 7.26 (1H, t, Ph), 7.36 (2H, t, Ph), 11.19 (1H, br, NH); FAB-MS m/z 344 (M + +H). Anal. calcd for C 19 H 25 N 3 O 3 ·H 2 O: C, 63.14; H, 7.53; N, 11.63. Found: C, 63.37; H, 7.67; N, 11.70. 
6-Benzyl-1-[5-(carbamoyl)pentyl]-5-isopropyluracil (16)
This compound was obtained from 11 in 46% yield as a foam by the procedure described for the preparation of 15: UV (MeOH) λ max 274 nm (ε 10800), λ min 239 nm (ε 1800); 1 H NMR (DMSO-d 6 ) δ 1.09-1.15 (2H, m, NCH 2 CH 2 CH 2 ), 1.16 (6H, d, CHMe 2 ), 1.34-1.40 (4H, m, NCH 2 CH 2 CH 2 CH 2 CH 2 ), 1.96 (2H, t, CH 2 CONH 2 ), 2.82 (1H, sept, CHMe 2 ), 3.53 (2H, t, NCH 2 ), 4.04 (2H, s, CH 2 Ph), 6.67 (1H, br, CONH), 7.18 (2H, d, Ph plus 1H, CONH), 7.26 (1H, t, Ph), 7.36 (2H, t, Ph), 11.21 (1H, br, NH); FAB-MS m/z 358 (M + +H). Anal. calcd for C 20 H 27 N 3 O 3 : C, 67.20; H, 7.61; N, 11.76. Found: C, 67.01; H, 7.83; N, 11.60. 
Materials and Methods: Virology

Cell line and viruses
MT-4 cells (Miyoshi et al., 1982) were used in all the experiments. The cells were grown and maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin G, and 100 µg/ml streptomycin (culture medium). Two strains of HIV-1 (III B and III B-R ) and one strain of HIV-2 (EHO) (Pauwels et al., 1990) were used for the anti-HIV assay. The III B-R strain is an MKC-442-resistant mutant containing a single amino acid change (Tyr-181→Cys) in the RT (Baba et al., 1994) . The virus was propagated and titrated in MT-4 cells.
Antiviral assay
Inhibitory effects of the compounds on HIV replication were monitored by the inhibition of virus-induced cytopathicity in MT-4 cells. Briefly, the cells were suspended at 1×10 5 cells/ml and infected with HIV at a multiplicity of infection of 0.02. Immediately after infection, 100 µl of the cell suspension was placed into each well of a flat-bottomed microtitre tray containing various concentrations of the test compounds. After a 4 day incubation at 37°C, the number of viable cells was determined by the 3-(4,5-dimethyl-thiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) method (Pauwels et al., 1988) . Cytotoxicity of the compounds for mockinfected MT-4 cells was also assessed by the MTT method.
Results
Chemistry Fig. 4 shows a synthetic route to the desired compounds which have ω-functionalized acyclic structures of different lengths. As reported in our previous study (Tanaka et al., 1995) , 2 can be readily prepared from 1 in a high overall yield by protecting the N3-position with a phenacyl group and subsequent acidic hydrolysis of the ethoxymethyl group. Alkylation at the N1-position of 2 with Y-(CH 2 ) n -Br, where Y is an alkoxycarbonyl group, was carried out in DMF in the presence of K 2 CO 3 at 100°C for 1 h to give 3-7 (in the preparation of 7, 3-bromo-1-propanol was used; isolated yields are given in parentheses). The use of methyl 3-bromopropionate (n=2, Y=CO 2 Me) as an alkylating agent in this reaction resulted in complete recovery of 2, due to preferential β-elimination of the reagent which generates a characteristic stench of methyl acrylate.
A trend can be seen that the isolated yields of 3-6 decrease according to the bulkiness of the alkylating agent used. In fact, their preparation uniformly gave a less polar byproduct (TLC solvent system: hexane:EtOAc; 2:1). These byproducts showed the same m/z value of a protonated positive molecular ion [M+H] + as 3-6 and their yield was found to increase in order of n: 7% (n=1), 26% (n=3), 34% (n=4), 40% (n=5). In one instance, when ethyl 6-bromocaproate was used in the reaction with 2, compound 6 and a byproduct were obtained in 58% and 40% yields, respectively. FAB-Mass spectra of both products showed their [M + +H] at m/z 505. Although these products gave a similar UV absorption pattern due to the presence of the N3-phenacyl group, a significant difference was observed in the 1 H NMR chemical shift of the ε-methylene resonances: 6, 3.68 ppm versus the less polar byproduct, 4.27 ppm (see experimental part). When this byproduct was treated with Zn/AcOH, 6-benzyl-5-isopropyluracil was obtained in 55% yield as the sole isolatable product. These facts suggest that the byproduct was derived from O-alkylation of 2, presumably due to steric hindrance of the 6benzyl group. Formation of a less polar byproduct was also observed in the preparation of 7.
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Compounds 3-6 were reductively deprotected by reacting with zinc powder in refluxing AcOH to give 8-11 in 73-90% yields. Compound 12 was prepared in 41% overall yield from 7 by initial acetylation followed by Zn/AcOH and then deacetylation (the acetylation of 7 was carried out for the purification of dephenacylated product). Ammonolysis of 8 and 9 was carried out by using 25% aqueous NH 4 OH at room temperature overnight to give 13 and 14. Because of the poor solubility of 10 and 11, these compounds were reacted with NH 3 /EtOH. However, the reaction appeared to be extremely sluggish even on heating at 100°C in a sealed tube. Although the use of 25% aqueous NH 4 OH in combination with pyridine as a co-solvent resulted in the complete consumption of the starting material (in a sealed tube, 100°C, overnight), a considerable amount of the corresponding carboxylic acid derivative was also detected by TLC (CHCl 3 :EtOH; 9:1), which could not be removed by silica gel column chromatography. Analytically pure 15 and 16 were obtained after purification of the reaction mixture by alumina column chromatography.
Anti-HIV activity
Compounds 8-16 were evaluated for their inhibitory activity against HIV replication in MT-4 cells and the results are summarized in Table 1 . The procedure to measure anti-HIV activity has been described previously (Pauwels et al., 1987) . The HTLV-III B strain of HIV-1, its MKC-442-resistant strain, and EHO strain of HIV-2 were used for the assay.
Discussion
The results of the inhibition assays are reported in Table 1 . All the compounds showed selective inhibition of HIV-1 and not HIV-2. The measured inhibitions for each of the analogues are significantly less than those for MKC-442. The decrease in potency observed for all of the analogues suggests either no additional hydrogen bonds have been formed or any binding energy gained by the inhibitors on forming hydrogen bonds to the receptor is lost by the increased desolvation energy of the polar moiety.
The large differences in the EC 50 values, particularly for the ester analogues indicates there may be some hydrogen bonds forming, since the main differences are the lengths of the alkyl chains and thus the position of the hydrogen bonding groups, not the desolvation energies of the polar atoms. The most potent of these is compound 8 (n=1, EC 50 =0.77 µM), which possesses a (methoxycarbonyl)methyl group.
The models predict this is capable of adopting conformations to hydrogen bond to either the hydroxyl of Tyr-318 or a water molecule hydrogen bonding to the amide nitrogen of Lys-103. The low potency of the corresponding amide 3 (n=1, EC 50 =10 µM) is expected since modelling indicates the amide group would be positioned in an energetically unfavourable environment deep inside the hydrophobic NNRTI binding pocket. The results in Table 1 also demonstrate the alkyl chain of three carbon atoms provides a favourable length to attach the hydrophilic groups: the ester 9 (EC 50 =1.6 µM), the amide 14 (EC 50 =2.2 µM), or the alcohol 12 (EC 50 =4.2 µM). The relative ranking of these results is consistent with the modelling but the overall EC 50 values are 100-fold in excess of the value for MKC-442.
The results for compounds with n>3 are less consistent with predictions. The N1-(ethoxycarbonyl)alkyl substituents of n=4 (10, EC 50 =38 µM) and n=5 (11, EC 50 =88 µM) are remarkably unfavourable. In contrast, the corresponding amides 15 (EC 50 =6.9 µM) and 16 (EC 50 =1.8 µM), which are capable of forming hydrogen bonds, inhibit HIV-1 with inhibition comparable to the n=3 compounds. Unfortunately none of the analogues showed any inhibition to the MKC-442-resistant mutant (HIV-1 IIIB-R with Tyr-181→Cys).
In conclusion, hydrogen bonding may provide specificity to inhibitor binding, but these results serve to emphasize that the hydrophilic effect of the desolvation energy of the polar moiety will frequently result in an unfavourable contribution to the free energy of binding.
